Media headlines about ContraFect Corporation (NASDAQ:CFRX) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ContraFect Corporation earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.8746991193368 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:

Shares of ContraFect Corporation (CFRX) traded down $0.06 on Tuesday, hitting $0.96. 38,800 shares of the stock were exchanged, compared to its average volume of 76,845. ContraFect Corporation has a fifty-two week low of $0.80 and a fifty-two week high of $2.70.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect ContraFect Corporation (CFRX) Stock Price” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-contrafect-corporation-cfrx-stock-price/1703218.html.

About ContraFect Corporation

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Insider Buying and Selling by Quarter for ContraFect Corporation (NASDAQ:CFRX)

Receive News & Ratings for ContraFect Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.